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ErB3 KO and Mutant Ovarian Cancer Cells Compromise Spheroid Shape in vitro Spheroid Assays
Receptor Signaling in ErbB3 KO and ErbB3 
Mutant OVCAR8 Cell Lines
         Par               V104L            V855A         KO












The more compact the spheroid formation, the greater the invasive behavior of the cancer cell line.
Figure 5: Both OVCAR 8 ErbB3 KO and Mutant ErbB3 V104L and V855A form looser spheroids than parental OVCAR 8, whereas ErbB2 KO make tighter, compact 
spheroids. 10,000 cells were plated into cell-repellent plates and imaged every two hours to view spheroid formation. All cell lines express GFP (green). YoY3 dye (red) was 
used to visualize cell death. Using ImageJ, the area and circumference of spheroids was measured. Circularity, a ratio measurement (4π*[Area]/[Perimeter]2) was calculated at 24 
and 48 hours to compare spheroid compactness.. 
Proliferation Assay




Exogenous expression of 
ErbB3 mutants
Transfecting plasmids that express 
ErbB3 mutants in OVCAR 8 ErbB3 
knockout cells
Stabilizing Cell Lines
Selection of cells expressing mutant 
ErbB3 by treatment with G418
Checking Transfection 
Efficiency
Labeled cells with 
anti-HA-Alexa 647, fixed and 
imaged to identify the 
percentage of transfected cells
Cell Sorting
Used flow cytometry to select for 
successfully transfected cells, using 
tags, to create a cell line with 
maximum expression of oncological 
mutations 
Spheroid Assays
Model aggregation of 
cancer cells that occurs 







Measuring the effect of 
receptor loss or mutation on 
cell growth rate
ErbB3 gain of function mutations may alter interactions with 
ErbB2 and affect spheroid formation and spreading.
Figure 1: Diagram of ErbB3 
Hotspot Mutations that have 
been identified in many types of 
cancers. 
The ErbB family of receptor tyrosine kinases are 
often mutated or overexpressed in cancer making 
them important targets for cancer therapy. 
The ErbB family activates signaling pathways 
leading to proliferation, growth and drug resistance.
ErbB3, one member of the ErbB family, has limited 
kinase activity and is thought to favor 
heterodimerization with ErbB2.
Mutations in ErbB3 that fall within specific 
hotspots have been identified in a variety of cancers 
(Figure 1) 
Why Ovarian Cancer?
➢ 5th leading cause of cancer deaths in women in 
the U.S.
➢ Relapse rate is 75%.
➢ Multiple ErbB receptors as well as the 
interacting receptor, Met, are expressed in 
ovarian cancer making it a good model to study 
ErbB interactions
➢ Ovarian cancer is thought to disseminate 
through the peritoneal cavity as free-floating 
cancer spheroids.
Figure 2: ErbB3/ErbB2 
Heterodimerization ErbB3 can 
adopt an active conformation when 
bound to a ligand, heregulin. ErbB3 
can form homo- and hetero-dimers 
which activates different pathways. 
By understanding how ErbB3 is activated in 
ovarian cancer and how the activation affects 
cell adhesion, therapies can be developed to 
reduce ovarian cancer relapse. 
References
Figure 7: Protein Analysis of OVCAR 8 cell lines. Cells were plated as a monolayer 
+/- stimulation with 12 nM HRG for 2 minutes. Fluorescent westerns show the 
expression level of ErbB2, MET, ErbB3 and Akt (downstream signaling protein) in 
OVCAR 8 Parental (Par), ErbB3 V104L, V855A and ErbB3 KO.
Spheroid Spreading on Fibronectin
Figure 4: Proliferation of OVCAR8 cell lines as 
monolayers. Cells were plated for 24 hours in media 
with 10% Fetal Bovine Serum (FBS) to allow them to 
attach to the plate. Proliferation was assessed using an 
XTT colorimetric assay at 0, 24 and 48 hours 
incubation in complete media containing 10% FBS or 
Serum Free Media (SFM) to measure the effect of 
ErbB3 mutations on growth rate with or without 
serum. 
Figure 6:Spheroids on Fibronectin Spheroids are placed on 
fibronectin  to mimic how spheroids may interact and spread on 
epithelial membranes on tissues and organs in the body.
OVCAR8 ErbB3 V104L exhibits serum-independent growth as a 
monolayer suggesting that this mutant may activate proliferation pathways 
in the absence of ligand. This is also supported by the phosphorylation of 
MET in the absence of ligand. Surprisingly, ErbB3 KO’s rate of growth is 
faster than the parental in 10% FBS between 24 to 48 hours. 
ErbB3 KO and V104L and V855A mutations result in less compact 
spheroids compared to parental and ErbB2 KO spheroids. 
Certain oncogenic mutations in ErbB3 may improve ErbB3 interactions 
with MET.
Targeted therapies have focused on ErbB2/ErbB3 interactions as key oncogenic 
partners. However, the importance of ErbB3/MET interactions should not be ignored 
when designing future therapies.
Circularity of Spheroids at 48 Hours
Area of Spheroids at 24 Hours Area of Spheroids at 48 Hours Area of Spheroids at 48 Hours
N=4
Figure 3: Expression of HA-ErbB3 
mutants in transfected OVCAR8 
cells. GFP+ cells (green) were labeled 
with anti-HA-Alexa647 (red), fixed 
with 2% paraformaldehyde and imaged 
on a confocal microscope. 
V104L V855A
Figure 8: Loss of ErbB3 and ErbB2 in OVCAR8 
cells further loosens spheroids even after 48 hours.
Examine spheroid formation and 
receptor interactions of double 
knockout (ErbB2 and ErbB3) 
OVCAR 8 cells to see which effect 
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(Co-IP) assays to determine 
whether mutant ErbB3 increases 
ErbB3/Met interactions in the 
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